- Home
- INSG vs ACRS Comparison
INSG vs ACRS Comparison
Compare INSG & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INSG
- ACRS
- Stock Information
- Founded
- INSG 1996
- ACRS 2012
- Country
- INSG United States
- ACRS United States
- Employees
- INSG N/A
- ACRS N/A
- Industry
- INSG Telecommunications Equipment
- ACRS Biotechnology: Pharmaceutical Preparations
- Sector
- INSG Telecommunications
- ACRS Health Care
- Exchange
- INSG Nasdaq
- ACRS Nasdaq
- Market Cap
- INSG 111.5M
- ACRS 127.6M
- IPO Year
- INSG 2000
- ACRS 2015
- Fundamental
- Price
- INSG $8.48
- ACRS $1.30
- Analyst Decision
- INSG Buy
- ACRS Strong Buy
- Analyst Count
- INSG 3
- ACRS 7
- Target Price
- INSG $13.00
- ACRS $11.67
- AVG Volume (30 Days)
- INSG 87.2K
- ACRS 832.4K
- Earning Date
- INSG 05-08-2025
- ACRS 05-08-2025
- Dividend Yield
- INSG N/A
- ACRS N/A
- EPS Growth
- INSG N/A
- ACRS N/A
- EPS
- INSG 0.10
- ACRS N/A
- Revenue
- INSG $191,244,000.00
- ACRS $17,777,000.00
- Revenue This Year
- INSG $2.53
- ACRS N/A
- Revenue Next Year
- INSG $11.55
- ACRS $425.96
- P/E Ratio
- INSG $81.58
- ACRS N/A
- Revenue Growth
- INSG 14.32
- ACRS N/A
- 52 Week Low
- INSG $3.70
- ACRS $0.95
- 52 Week High
- INSG $20.67
- ACRS $5.17
- Technical
- Relative Strength Index (RSI)
- INSG 53.95
- ACRS 43.35
- Support Level
- INSG $8.00
- ACRS $1.20
- Resistance Level
- INSG $8.60
- ACRS $1.31
- Average True Range (ATR)
- INSG 0.44
- ACRS 0.10
- MACD
- INSG 0.13
- ACRS 0.02
- Stochastic Oscillator
- INSG 81.16
- ACRS 43.04
About INSG Inseego Corp.
Inseego Corp is into the design and development of fixed and mobile wireless solutions (4G and 5G NR), Industrial Internet of Things and cloud solutions for enterprises, service providers, small and medium-sized businesses, governments, and consumers around the globe. Its products and services include intelligent mobile hotspots, wireless routers for IoT applications, USB modems, integrated telematics and mobile tracking devices, which are supported by applications software and cloud services designed to enable customers to easily analyze data insights and configure and manage their hardware. It generates maximum revenue from United States and Canada. The company also has a presence in Australia and Europe (including United Kingdom).
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.